Risk factor
Poor trading liquidity
Profitability factor
Favourable price performance
About
Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology,...
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, of fair value on EV/EBIT
Target Price
The average target price of SLV.WA is 50 and suggests 12% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommendation
Buy
Sell